Integrative drug discovery for Parkinson disease with DIMER

DIMER applied to Parkinson disease integrates gene sets, transcriptomes, and single-nucleus profiles to identify 423 drug repurposing candidates and 22 compounds from 1.82 million virtual screening.

• Why it matters: Parkinson disease genetics is interconnected and cell-context dependent, so drug discovery needs methods that connect network repurposing with target-directed screening while accounting for disease expression programs.
• What they did: DIMER links shared disease-associated gene sets to drug-target interactions, disease transcriptomes, and single nucleus expression, then uses a pretrained compound–protein interaction model plus ligand-informed ranking for virtual screening.
• The result: In human midbrain organoids exposed to 6-hydroxydopamine, four repurposing candidates—polydatin, fedratinib, sorafenib, and venlafaxine—attenuated loss of dopamine neuron marker signals.